Lu (Maggie) Qian: How Adaptive Trial Design Reveals Treatment Effects in COVID-19
Lu (Maggie) Qian, Founder at Zetyra, Creator and Editor at Evidence in the Wild, shared a post on LinkedIn:
”Four randomized controlled trials of IL-6 receptor antagonists in COVID-19 showed no significant benefit.
Then Remap-cap reported that tocilizumab and sarilumab both worked, with >99.9% posterior probability of superiority and confirmed survival benefit at six months.
The difference wasn’t the drug. It was the design.
Remap-cap used a multifactorial platform design.
Patients were randomized across multiple domains simultaneously, corticosteroids, IL-6 antagonists, anticoagulation, antivirals, convalescent plasma, and a Bayesian model learned which components worked, and for whom, across all domains at once.
Earlier trials enrolled less severely ill patients.
Remap-cap enrolled ICU patients.
It allowed concurrent dexamethasone.
And it had the statistical machinery to isolate the IL-6 effect on top of steroids.
It detected what single-question trials could not.
Then the same platform revealed a different vulnerability.
While the corticosteroid domain was randomizing hydrocortisone vs. no hydrocortisone, the recovery trial announced that dexamethasone reduced mortality.
Overnight, 93% of patients were receiving corticosteroids as background therapy regardless of randomization.
The adaptive engine worked as designed. It just didn’t work fast enough.
A simple, large trial answered the question before the more sophisticated Bayesian platform could.
No amount of pre-specification can fully anticipate the information environment a trial will encounter.
Meanwhile, most Phase III trials use covariate-adaptive randomization, and then analyze the data as though they used simple randomization, leaving power on the table.
Corrected inference methods exist.
The carat R package implements them.
Most practicing biostatisticians haven’t heard of it.
Randomization determines what a trial can learn, not just who gets what treatment.
It should be one of the first design decisions.
Not the last.”
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes
-
Jul 21, 2026, 13:10Paolo Zamboni: Chronic Cerebrospinal Venous Insufficiency Hypothesis in Multiple Sclerosis
-
Jul 21, 2026, 13:05Danai Poutakidou։ The Diagnostic Pitfalls of Unexpected PT/INR Prolongation
-
Jul 21, 2026, 13:00Kefah Mokbel: Beyond Thromboprophylaxis – Enoxaparin’s Emerging Anticancer Signal
-
Jul 21, 2026, 12:56Emmanuel Velazquez-Alvarez: Bridging Innovation and Clinical Practice
-
Jul 21, 2026, 12:53Sandrine Bouteille: A Milestone Presentation at ISTH 2026
-
Jul 21, 2026, 12:40Kalled Musallam: A Comprehensive Review of Thalassemia